IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Quality of Co-Trimoxazole Tablets Used for Management of Opportunistic Infections in HIV/AIDS Patients

Author: UPLOADED BY-ADMIN, APPOLINARY A.R. KAMUHABWA, MARIYAH H. SAIFUDDIN, BETTY MAGANDA, ELIANGIRINGA KAALE
Abstract: This study was carried out to determine the quality of commercially available co-trimoxazole tablets that are used for prophylaxis and treatment of opportunistic infections in people living with HIV and AIDS (PLWHA) in Dar es Salaam, Tanzania. Different batches and brands of co-trimoxazole tablets obtained from care and treatment clinics and private pharmacies were assessed for weight uniformity, crushing strength, friability, disintegration time, thickness, dissolution and assay for trimethoprim and sulphamethoxazole in the tablets. All of the products evaluated complied with pharmacopoeial specifications for disintegration time, weight uniformity, friability and hardness. However, some brands failed content and dissolution tests. The mean thickness of the tablets ranged from 3mm to 5mm. The mean disintegration times ranged from 0.26 ± 0.03min to 5.18 ± 5.51min. Fifteen out of the seventeen tested products gave an assay value within the specified limit (93%-107%), while the other two gave an assay value below the specified limit. Fifteen of the tested products released more than 70% (75.81%-112.77%) of trimethoprim, while one product released more than 70% (72.16% - 113.12%) of sulphamethoxazole after one hour. The fact that some brands of co-trimoxazole did not meet the United States Pharmacopoeia and British Pharmacopoeia official requirements in terms of dissolution and content uniformity is an indication of the existence of sub-standard products in the market. The use of such products, especially in PLWHA is likely to cause microbial resistance to co-trimoxazole, thus leading to treatment failure.
Keyword: Co-trimoxazole, Quality, HIV/AIDS, Opportunistic Infections
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free